Literature DB >> 15842439

ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques.

Peter H Stone1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842439      PMCID: PMC6932340          DOI: 10.1111/j.1542-474X.2005.10203.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


× No keyword cloud information.
  55 in total

1.  ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology.

Authors:  M H Crawford; S J Bernstein; P C Deedwania; J P DiMarco; K J Ferrick; A Garson; L A Green; H L Greene; M J Silka; P H Stone; C M Tracy; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; G Gregoratos; R O Russell; T H Ryan; S C Smith
Journal:  J Am Coll Cardiol       Date:  1999-09       Impact factor: 24.094

2.  Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test.

Authors:  E G Nabel; P Ganz; J B Gordon; R W Alexander; A P Selwyn
Journal:  Circulation       Date:  1988-01       Impact factor: 29.690

3.  Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia.

Authors:  S D Rosen; E Paulesu; P Nihoyannopoulos; D Tousoulis; R S Frackowiak; C D Frith; T Jones; P G Camici
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

4.  Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up.

Authors:  T Von Arnim
Journal:  J Am Coll Cardiol       Date:  1996-07       Impact factor: 24.094

5.  A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory.

Authors:  B L Sharaf; D O Williams; N J Miele; R P McMahon; P H Stone; P Bjerregaard; R Davies; A D Goldberg; M Parks; C J Pepine; G Sopko; C R Conti
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

6.  Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? An observational study of myocardial ischaemia and its relation to coronary anatomy.

Authors:  D J Patel; A H Gomma; C J Knight; D A Mulcahy; C A Wright; H J Purcell; K M Fox
Journal:  Eur Heart J       Date:  2001-11       Impact factor: 29.983

7.  Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients.

Authors:  K M Akkerhuis; P A Klootwijk; W Lindeboom; V A Umans; S Meij; P P Kint; M L Simoons
Journal:  Eur Heart J       Date:  2001-11       Impact factor: 29.983

8.  Asymptomatic Cardiac Ischemia Pilot (ACIP) Study. Relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease.

Authors:  P H Stone; B R Chaitman; R P McMahon; T C Andrews; G MacCallum; B Sharaf; W Frishman; J E Deanfield; G Sopko; C Pratt; A D Goldberg; W J Rogers; J Hill; M Proschan; C J Pepine; M G Bourassa; C R Conti
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

9.  The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress.

Authors:  A C Yeung; V I Vekshtein; D S Krantz; J A Vita; T J Ryan; P Ganz; A P Selwyn
Journal:  N Engl J Med       Date:  1991-11-28       Impact factor: 91.245

10.  Effects of dosing intervals on the development of tolerance to high dose transdermal nitroglycerin.

Authors:  E G Nabel; J Barry; M B Rocco; K Mead; A P Selwyn
Journal:  Am J Cardiol       Date:  1989-03-15       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.